Pramodini Medicare Plans 51% Mahathi Stake for ₹6.12 Crore
Key highlights
- Pramodini Medicare proposes to acquire 51%, or 1,020 equity shares, of Mahathi Imaging.
- The detailed transaction summary cites indicative cash consideration of ₹6.12 crore, subject to final valuation.
- Mahathi Imaging reported FY26 turnover of ₹5.49 crore, versus ₹5.21 crore in FY25.
- The proposed transaction has a 90-day completion target and may be extended by 30 days.
powered by IRIS

Pramodini Medicare Limited has agreed to acquire a 51% stake in Mahathi Imaging and Diagnostics Private Limited for an indicative cash consideration of ₹6.12 crore, subject to valuation and definitive agreements. The proposed purchase of 1,020 equity shares would make Mahathi Imaging a subsidiary after completion.
Know Pramodini Medicare inside out
Results, valuation, peers and who's buying, in one view.
What has Pramodini Medicare agreed to acquire?
Pramodini Medicare has agreed to acquire 1,020 equity shares, representing 51% of Mahathi Imaging and Diagnostics Private Limited's paid-up equity capital. The board approved the proposal at its meeting on 13 November 2026, while the disclosure was filed with the NSE on 14 November 2026.
The proposed stake gives Pramodini Medicare a controlling interest rather than a minority financial investment. The company has stated that Mahathi Imaging would become its subsidiary once the transaction is completed. However, the acquisition remains conditional and was not a completed purchase as of the filing date.
The target is a diagnostic imaging company incorporated in Andhra Pradesh on 29 November 2018. A source summary described it as Tirupati-based, although the exchange-related material primarily identifies it as Mahathi Imaging and Diagnostics Private Limited.
What is the proposed acquisition price and timeline?
The indicative consideration disclosed in the detailed transaction summary is ₹6.12 crore in cash, equivalent to ₹60,000 per equity share for 1,020 shares. The final consideration will be determined through a valuation report prepared by a merchant banker or independent valuer and will be recorded in the definitive share purchase agreement, or SPA.
The transaction is targeted for completion within 90 days from acceptance of the letter, with a possible extension of 30 days. This schedule is subject to completion of due diligence, final valuation and execution of the SPA.
Some announcement summaries carry a transaction value of ₹0.01 crore, which conflicts with the separate disclosure of an indicative ₹6.12 crore consideration. The available material does not explain the difference. Until the SPA and valuation report are finalised, ₹6.12 crore should be treated as the stated indicative amount rather than a settled purchase price.
What financial profile does Mahathi Imaging bring?
Mahathi Imaging reported turnover of ₹5.49 crore in FY26, compared with ₹5.21 crore in FY25 and ₹5.57 crore in FY24. The FY26 figure was higher than the preceding year but remained below its FY24 turnover.
The disclosed turnover history provides a view of the target's operating scale, but the materials do not state its profit, assets, debt, cash flow or customer base. As a result, the financial impact of consolidation on Pramodini Medicare cannot be fully calculated from the information currently available.
A separate summary linked the target's FY26 turnover of about ₹5.5 crore to Pramodini Medicare's reported FY26 revenue of ₹62 crore. That comparison indicates the target is materially smaller than the acquirer, though revenue alone does not establish the future contribution to consolidated profit or cash generation.
Got a follow-up? Ask IRIS
Why are due diligence and valuation important to this transaction?
Due diligence and definitive agreements are the principal conditions before Pramodini Medicare can complete the acquisition. Due diligence allows the buyer to review the target's financial, legal, operational and other relevant records before taking control.
The valuation report is equally important because the final consideration has not been fixed. Although ₹6.12 crore has been identified as indicative consideration, the SPA will set out the final transaction terms after the valuation exercise. The material does not disclose the seller's identity, payment milestones, representations, liabilities or other SPA conditions.
The acquisition was disclosed under Regulation 30 of the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements regulations. Such disclosures are intended to inform shareholders about material board decisions, but a board approval does not itself confirm that the transaction has closed.
How could the proposed deal affect Pramodini Medicare and investors?
The proposed acquisition would expand Pramodini Medicare's presence in diagnostic imaging through a majority-owned subsidiary, if the stated conditions are met. For investors, the immediate significance is the proposed addition of a business with FY26 turnover of ₹5.49 crore and the associated cash commitment at the final valuation.
The eventual impact on Pramodini Medicare's financial position will depend on the final acquisition price, Mahathi Imaging's profitability, integration costs and any obligations identified during due diligence. The disclosed turnover figures do not show whether the target will contribute profit after acquisition.
The proposal was approved alongside the company's results. A separate disclosure noted that Pramodini Medicare's consolidated half-year revenue rose 34%, while profit after tax fell 10% and operating cash flow was negative at ₹56.97 crore. These reported conditions make the final cash outlay, financing approach and completion terms relevant points for shareholders to monitor.
Conclusion
Pramodini Medicare's proposed 51% purchase of Mahathi Imaging is a planned controlling acquisition with an indicative cash consideration of ₹6.12 crore. The target's FY26 turnover of ₹5.49 crore gives the transaction a defined operating context, but the available disclosures do not provide enough information to assess its prospective profit contribution or full financial effect.
The next disclosed milestones are completion of due diligence, an independent or merchant-banker valuation, execution of the SPA and closing within 90 days from letter acceptance, subject to a further 30-day extension. Investors should also watch for clarification of the conflicting ₹0.01 crore figure appearing in some announcement summaries and confirmation of the final consideration.


